Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biome Australia Ltd ( (AU:BIO) ) has shared an announcement.
Biome Australia has secured a two-year extension to its exclusive supply agreement with long-standing strain partner Probiotical SpA, pushing the deal’s expiry from June 2026 to 2028 on unchanged commercial terms. The renewed arrangement underpins Biome’s supply chain as it builds out its portfolio of clinically supported probiotic-based complementary medicines for practitioners and patients across Australia and key overseas markets.
The extension gives both companies greater certainty to continue executing their international expansion plans as Biome scales its footprint in Australia, Canada, the U.K., Ireland and New Zealand. In parallel, Biome is progressing an Australian manufacturing onshoring program, which is intended to strengthen its production capabilities and support future growth, with further updates flagged for 2026.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
More about Biome Australia Ltd
Biome Australia Limited is an Australian developer and marketer of evidence-based live biotherapeutics and complementary medicines, distributed domestically and internationally. Working with leading microbiome research organisations, it has created its flagship Activated Probiotics and Activated Therapeutics ranges, which use innovative delivery technologies and are sold via practitioner-only channels to address conditions such as low mood, sleep issues, bone health, iron malabsorption, mild eczema and IBS.
Average Trading Volume: 197,761
Technical Sentiment Signal: Sell
Current Market Cap: A$64.98M
Find detailed analytics on BIO stock on TipRanks’ Stock Analysis page.